Company NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 03:59:53 2024-02-23 pm EST 5-day change 1st Jan Change
15.2 USD -0.26% Intraday chart for NovoCure Limited -5.82% +1.81%

Business Summary

NovoCure Limited is a global oncology company, which is principally engaged in the development, manufacturing and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields therapy has applicability across solid tumor types and lines of therapy. It is conducting phase three pivotal studies evaluating the use of TTFields in non-small cell lung cancer (NSCLC), ovarian cancer, brain metastases from NSCLC, and pancreatic cancer. The Company's key priorities are to drive commercial adoption of Optune and Optune Lua, its commercial TTFields devices. The Company markets Optune in the United States, Germany, Japan and other countries. The Company markets Optune Lua in the United States and European Union. It also has a licence to market Optune in China, Hong Kong, Macau and Taiwan.

Number of employees: 1,453

Sales per Business

USD in Million2022Weight2023Weight Delta
Tumor Treating Fields
100.0 %
538 100.0 % 509 100.0 % -5.30%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
68.7 %
407 75.7 % 350 68.7 % -14.05%
Germany
11.8 %
46 8.6 % 60 11.8 % +30.55%
Other EMEA
8.7 %
31 5.7 % 44 8.7 % +44.87%
Japan
6.2 %
33 6.1 % 32 6.2 % -3.40%
Greater China
4.6 %
21 4.0 % 23 4.6 % +8.87%

Managers

Managers TitleAgeSince
Chief Executive Officer 56 01-12-31
Director of Finance/CFO 45 14-05-31
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer 50 Jan. 03
Chief Operating Officer 66 12-01-04
Investor Relations Contact - 21-06-30
General Counsel 48 17-12-31
Corporate Officer/Principal - -
Corporate Officer/Principal 46 08-02-29
Corporate Officer/Principal 44 09-12-31

Members of the board

Members of the board TitleAgeSince
Chairman 61 03-12-31
Director/Board Member 62 11-08-04
Director/Board Member 66 18-05-30
Director/Board Member 60 21-02-04
Director/Board Member 66 18-07-24
Director/Board Member 68 05-12-31
Chief Executive Officer 56 01-12-31
Director/Board Member 64 17-05-09
Director/Board Member 42 23-03-27
Director/Board Member 52 23-02-22

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 107,093,432 105,517,632 ( 98.53 %) 0 98.53 %

Shareholders

NameEquities%Valuation
Fidelity Management & Research Co. LLC
14.94 %
15,962,767 14.94 % 222 M $
Vanguard Fiduciary Trust Co.
9.133 %
9,759,098 9.133 % 136 M $
The Vanguard Group, Inc.
9.132 %
9,759,087 9.132 % 136 M $
Capital Research & Management Co. (International Investors)
8.325 %
8,896,076 8.325 % 124 M $
Capital Research & Management Co. (International Investors)
8.293 %
8,861,871 8.293 % 123 M $
8,141,397 7.619 % 113 M $
BlackRock Advisors LLC
6.883 %
7,355,376 6.883 % 102 M $
Baillie Gifford & Co.
4.769 %
5,095,777 4.769 % 71 M $
Baillie Gifford & Co.
4.529 %
4,840,141 4.529 % 67 M $
3,863,549 3.615 % 54 M $

Company contact information

NovoCure Ltd.

No. 4 The Forum Grenville Street

JE2 4UF, St. Helier

+44 15 3475 6700

http://www.novocure.com
address NovoCure Limited(NVCR)

Sales per region

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
15.22 USD
Average target price
25 USD
Spread / Average Target
+64.26%
Consensus
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW